JP2004149521A5 - - Google Patents

Download PDF

Info

Publication number
JP2004149521A5
JP2004149521A5 JP2003346699A JP2003346699A JP2004149521A5 JP 2004149521 A5 JP2004149521 A5 JP 2004149521A5 JP 2003346699 A JP2003346699 A JP 2003346699A JP 2003346699 A JP2003346699 A JP 2003346699A JP 2004149521 A5 JP2004149521 A5 JP 2004149521A5
Authority
JP
Japan
Prior art keywords
salt
pioglitazone
solid preparation
metformin
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003346699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004149521A (ja
JP4236553B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2003346699A priority Critical patent/JP4236553B2/ja
Priority claimed from JP2003346699A external-priority patent/JP4236553B2/ja
Publication of JP2004149521A publication Critical patent/JP2004149521A/ja
Publication of JP2004149521A5 publication Critical patent/JP2004149521A5/ja
Application granted granted Critical
Publication of JP4236553B2 publication Critical patent/JP4236553B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003346699A 2002-10-07 2003-10-06 固形製剤 Expired - Lifetime JP4236553B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003346699A JP4236553B2 (ja) 2002-10-07 2003-10-06 固形製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002294045 2002-10-07
JP2003346699A JP4236553B2 (ja) 2002-10-07 2003-10-06 固形製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008125325A Division JP2008208141A (ja) 2002-10-07 2008-05-12 固形製剤

Publications (3)

Publication Number Publication Date
JP2004149521A JP2004149521A (ja) 2004-05-27
JP2004149521A5 true JP2004149521A5 (enExample) 2008-06-26
JP4236553B2 JP4236553B2 (ja) 2009-03-11

Family

ID=32064024

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003346699A Expired - Lifetime JP4236553B2 (ja) 2002-10-07 2003-10-06 固形製剤
JP2008125325A Pending JP2008208141A (ja) 2002-10-07 2008-05-12 固形製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008125325A Pending JP2008208141A (ja) 2002-10-07 2008-05-12 固形製剤

Country Status (25)

Country Link
US (1) US9101660B2 (enExample)
EP (1) EP1561472B2 (enExample)
JP (2) JP4236553B2 (enExample)
KR (2) KR20070119095A (enExample)
CN (1) CN100427143C (enExample)
AU (1) AU2003271103B2 (enExample)
BR (1) BR0315082A (enExample)
CA (1) CA2501587C (enExample)
CO (1) CO5700740A2 (enExample)
CR (1) CR7797A (enExample)
CY (1) CY1114863T1 (enExample)
DK (1) DK1561472T3 (enExample)
ES (1) ES2437072T5 (enExample)
IL (1) IL167835A (enExample)
MA (1) MA27487A1 (enExample)
MX (1) MXPA05003668A (enExample)
NO (1) NO332993B1 (enExample)
NZ (2) NZ539711A (enExample)
PL (1) PL219608B1 (enExample)
PT (1) PT1561472E (enExample)
RU (1) RU2357757C2 (enExample)
SI (1) SI1561472T1 (enExample)
UA (1) UA80991C2 (enExample)
WO (1) WO2004030700A1 (enExample)
ZA (1) ZA200503507B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
PL1677792T3 (pl) 2003-10-31 2016-05-31 Takeda Pharmaceuticals Co Stały preparat zawierający pioglitazon, glimepiryd i ester polioksyetylenosorbitanu z kwasem tłuszczowym
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
PL1878426T3 (pl) * 2005-04-26 2010-11-30 Sumitomo Dainippon Pharma Co Ltd Preparat w formie granulatu zawierający związek biguanidu
HRP20160679T1 (hr) 2005-12-22 2016-07-15 Takeda Pharmaceutical Company Limited Kruti pripravak koji sadrži senzibilizator inzulina
KR101220643B1 (ko) * 2006-08-16 2013-01-14 알리코제약(주) 사포그릴레이트 함유 경구투여 형태의 약제
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP4832271B2 (ja) * 2006-12-11 2011-12-07 花王株式会社 粉末圧縮錠剤
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
US8563500B2 (en) 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
CN101417130B (zh) * 2007-10-22 2010-10-06 鲁南制药集团股份有限公司 一种治疗ⅱ型糖尿病及其并发症的药物组合物
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2010084504A2 (en) * 2008-05-26 2010-07-29 Sun Pharmaceutical Industries Ltd. A stable, oral solid dosage form
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
RU2465896C2 (ru) * 2011-01-20 2012-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция пролонгированного действия
CN105125539A (zh) * 2015-08-05 2015-12-09 浙江华海药业股份有限公司 吡格列酮二甲双胍片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1380308B1 (en) 1996-07-12 2008-07-09 Daiichi Pharmaceutical Co., Ltd. Quickly disintegrable compression-molded materials and process for producing the same
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
AP1279A (en) * 1997-06-18 2004-05-20 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin.
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JPH1160476A (ja) 1997-08-25 1999-03-02 Taisho Pharmaceut Co Ltd 圧縮固形組成物
CA2320900C (en) 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ATE481090T1 (de) * 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
WO2000028989A1 (en) 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
WO2000038666A2 (en) 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
CA2371391A1 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
US6403121B1 (en) 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
JP2001335469A (ja) * 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
FR2812547B1 (fr) 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2002087965A (ja) * 2000-09-14 2002-03-27 Lion Corp 口中崩壊性アスピリン含有錠剤
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CA2492722A1 (en) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Production method of coated preparations

Similar Documents

Publication Publication Date Title
JP2004149521A5 (enExample)
RU2005113999A (ru) Твердый препарат
Poewe et al. Emerging therapies for Parkinson's disease
JP2014501780A5 (enExample)
JP2007504212A5 (enExample)
JP2010090168A5 (enExample)
JP2008526757A5 (enExample)
JP2006513238A (ja) 吸湿性薬物を含む非‐吸湿性製剤
CN104161752B (zh) 一种维格列汀组合物
JP2012520883A5 (enExample)
CA2514539A1 (en) Process for producing coated preparation
Alayoubi et al. Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics
JP2008520736A5 (enExample)
JP2019081811A5 (enExample)
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
JP2017222722A5 (enExample)
CA2530308A1 (en) 5ht2c receptor agonists for the treatment of diabetes and obesity
CN103228618A (zh) 新化合物及其医药用途
US20040235802A1 (en) Combinations comprising cox-2-inhibitors and aspirin
JP2011516544A5 (enExample)
Melamed et al. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy
BR112020003375A2 (pt) composições de amantadina, preparações das mesmas, e métodos de uso
EP2656856A2 (en) Tablet formulation comprising levodopa, carbidopa, entacapone providing extended release
JP2009522207A5 (enExample)
CA2565993A1 (en) Salt of 4-or 5- aminosalicylic acid